Cargando…
Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
BACKGROUND: Despite the use of modern immunochemotherapy regimens, a significant proportion of diffuse large B-cell lymphoma (DLBCL) patients will relapse. We proposed absolute lymphocyte count/absolute monocyte count ratio (ALC/AMC ratio) as a new prognostic factor in relapsed or primary refractory...
Autores principales: | Li, Yan-Li, Gu, Kang-Sheng, Pan, Yue-Yin, Jiao, Yang, Zhai, Zhi-Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033684/ https://www.ncbi.nlm.nih.gov/pubmed/24884604 http://dx.doi.org/10.1186/1471-2407-14-341 |
Ejemplares similares
-
Management of relapsed-refractory diffuse large B cell lymphoma
por: Raut, Lalit S., et al.
Publicado: (2014) -
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Harris, Leonard Jeff, et al.
Publicado: (2020) -
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell
Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020) -
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021) -
Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
por: Hood, Katelyn, et al.
Publicado: (2016)